<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1321">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537299</url>
  </required_header>
  <id_info>
    <org_study_id>20-008867</org_study_id>
    <secondary_id>1R01AG072301-01</secondary_id>
    <nct_id>NCT04537299</nct_id>
  </id_info>
  <brief_title>COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes</brief_title>
  <acronym>COVID-FIS</acronym>
  <official_title>COVID-FIS: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing Homes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in
      preventing an increase in the disease's progression and alleviate complications of
      coronavirus due to an excessive inflammatory reaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a pilot, randomized, placebo-controlled, single-center study of Fisetin in
      elderly nursing home participants with non-, mildly-, or moderately-symptomatic and confirmed
      SARS-CoV-2 infection.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in COVID-19 Severity</measure>
    <time_frame>baseline, Day 2, 7, 10, 14, 17, 30, 90 and 180</time_frame>
    <description>Ordinal Scale for Clinical Improvement (minimum=0 and maximum=8; higher score = worse outcome)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatment drug (Fisetin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fisetin</intervention_name>
    <description>~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 &amp; 1 and Days 8 &amp; 9)</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>3,3',4',7-tetrahydroxyflavone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo looks exactly like the treatment drug, but it contains no active ingredient</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or post-menopausal women age ≥65 years.

          2. Current nursing home resident.

          3. COVID-19 severity of moderate or less (according to World Health Organization
             (WHO)/National Institutes of Health (NIH) Severity Categorization OR SpO2 ≥ 85% on
             room air within previous 72 hours AND ≤ 2 L of oxygen by nasal cannula (or on room
             air) at time of enrollment.

          4. SARS-CoV-2 infection confirmed by PCR test at Mayo Clinic's Central Laboratory within
             10 days before randomization.

          5. Willing and able to provide written informed consent or have a legally authorized
             representative (LAR) who will provide informed consent.

        Exclusion Criteria:

          1. Presence of any condition that the Investigator or the subject's attending physician,
             physician's assistant, or nurse-practitioner believes would put the subject at risk or
             would preclude the patient from successfully completing the trial.

          2. Mechanically-ventilated.

          3. Pregnancy (note that only post-menopausal women will be enrolled).

          4. Severe or critical COVID19 (WHO/ NIH Severity Categorization) at time of
             randomization.

          5. Total bilirubin &gt;3X upper limit of normal or as per clinical judgment.

          6. Serum aspartate transaminase (AST) or alanine aminotransferase (ALT) &gt;4x the upper
             limits of normal or as per clinical judgment.

          7. Hemoglobin &lt;7 g/dL; white blood cell count ≤2,000/mm3 (≤2.0 x 109/L) or ≥20,000/mm3
             (≥20 x 109/L); platelet count ≤ 40,000/μL (≤40 x 109/L); absolute neutrophil count ≤1
             x 109/L; lymphocyte count &lt;0.3 x 109/L at screening or as per clinical judgment.

          8. Unstable (as per clinical judgment) major cardiovascular, renal, endocrine,
             immunological, or hepatic disorder.

          9. eGFR &lt;25 ml/ min/ 1.73 m2 or as per clinical judgment.

         10. Plasma and/or serum glucose &gt;300 or as per clinical judgment.

         11. Cystatin C &gt;3x upper limit of normal or as per clinical judgment.

         12. Human immunodeficiency virus infection.

         13. Known active hepatitis B or C infection.

         14. Invasive fungal infection.

         15. Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites.

         16. New/active invasive cancer except non-melanoma skin cancers as per clinical judgment.

         17. Known condition associated with major immunodeficiency as per clinical judgment.

         18. Known hypersensitivity or allergy to Fisetin.

         19. Subjects taking any of the medications listed in Protocol Appendix 1 may participate
             if they are otherwise eligible AND the medication can be safely held during the
             following times:

               -  Immediately before the 1st IP administration (Day 0) until at least 10 hours
                  after the 2nd IP administration (Day 1)

               -  Immediately before the 3rd IP administration (Day 8) until at least 10 hours
                  after the 4th IP administration (Day 9)

         20. Participation in other clinical trials involving treatment for COVID-19. Note that
             institutional standard of care treatment of COVID-19 including glucocorticoids,
             hydroxychloroquine, azithromycin, remdesivir, anti-spike antibodies, and/or
             convalescent plasma are not excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Kirkland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James L Kirkland, MD, PhD</last_name>
    <phone>507-266-9151</phone>
    <email>kirkland.james@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2020</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James L. Kirkland</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

